


Head of Novel Therapeutics, Dementia Research Centre, UCL; Chair NIHR dementia Translational Research Collaboration; Director NIHR UK Dementia Trials Network



We present results of the first trial of a TREM2 agonist in AD. This was a negative trial; nevertheless an important result in understanding the mechanism of action; it also shows ARIA can occur without removal of amyloid, informing theory on cause of ARIA.nature.com/articles/s41591-0…

Really enjoyed writing this paper with amazing leaders in AD treatments and biomarkers - how we need more than just anti-amyloid therapies; how developing tau therapies and biomarkers will shape treatment options as well as the patient pathway sciencedirect.com/science/ar…

It was a privilege to be a part of the conference - an amazing array of talent and knowledge in neuroscience - delighted to be a small part of it!
A couple of days of neuroscience excellence at the 8th @CamNeuro Symposium: Interventions & Recovery. So many great talks, loads of representation from our lab showcasing what everyone has been up to, & insightful public panel discussion on dementia!

A couple of days of neuroscience excellence at the 8th @CamNeuro Symposium: Interventions & Recovery. So many great talks, loads of representation from our lab showcasing what everyone has been up to, & insightful public panel discussion on dementia!

pleasure to be on #newsnight last night with @scott.mitchell3 remembering his fabulous wife, Barbara Windsor #dementia goals programme and urgent need to modernise dementia services to deliver disease changing treatments - the challenge is great but cannot wait #implementation

🔬Prof Cath Mummery (@cathmummery) chaired a session at #AAIC25 today discussing what a clinician may find important compared to patients. An important topic for making trial outcomes matter to people living with Alzheimer’s

Oh my, the jumps!! Happy sausage
A senior dog doing her best.. 🥺

At @UniofOxford it's time for the staff survey. Here's my answer to: "What is the main thing the University could do to help you to progress your career?" Please RT and respond similarly to the survey if you agree. It's the only way to get our points across!

Reminded how far things have moved in 3 years - two DMTs, blood biomarkers, innovation in clinical trials but just the beginning and need to push forwards
Starting now, @PhilipAlz chairs “Stimulating Innovation: Clinical Trials” with John Dwyer, @cathmummery, Andrew Pain and Cecilie Oliver

Liz Truss on Mark Carney. I cannot breathe it’s so funny. Self-awareness of a deceased mosquito. x.com/govt_corrupt/status/18…

Why academia is sleepwalking into self-destruction. My editorial @Brain1878 If you agree with the sentiments please RT. It's important for all our sakes to stop the madness academic.oup.com/brain/issue…

What a smashing way to celebrate #IWD2025! In just one week, the DRC at @UCLIoN had not 1️⃣ but 2️⃣ inaugural lectures from new female professors @JBar_UK & @cathmummery 💪🎉 Testament to their strength, talent & leadership. Onwards & upwards! 🚀 @UCLBrainScience

Our inRAD group developed international consensus on what a common minimum dataset for a real world registry in dementia should look like. Critical to understand/record treatment effects in a standardised way, and develop opportunities to work globally. gbr01.safelinks.protection.o…

UCL neuroscientist recognised with honorary MBE | UCL News - UCL – University College London @UCLIoN @UCLBrainScience ucl.ac.uk/news/2025/feb/ucl-…